Strattera Labeling Adds Bolded Warning For Severe Liver Injury
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly revises labeling following two cases of severe liver injury attributed to the attention deficit/hyperactivity disorder treatment. The company plans to issue a "Dear Health Care Professional" letter Jan. 3.